Please assess the completion status of the following clinical trial:

Trial Title: Benapenem PK Phase Ib Multiple-dose Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female healthy subjects, aged 18 \~ 45;~* Body weight ≥ 50 kg and body mass index 19.0 \~ 24.0 kg/m2;~* Prior to the test, physical examination, blood routine, urine routine, liver and kidney functions, and related examinations normal, or mild abnormalities in indicators while without clinical significance as indicated by the investigator~* Normal or mild abnormalities without clinical significance in the standard 12-lead ECG;~* Signing informed consent form~Exclusion Criteria:~* Regular smoking, alcohol abuse, and drug abuse;~* Use of drugs with known damage to an organ within three months;~* History of specific allergies, or history of drug allergy, especially those allergic to lactams and excipients of test drug;~* Febrile illnesses within three days before the screening;~* Patients with mental illness or psychotic disorder in the past;~* Past mental and nervous system diseases (epilepsy, stroke, cerebrovascular disorder, etc.), gastrointestinal disorder (such as stomach ulcers, gastritis, etc.) or disorder of other systems (such as cardiovascular, respiratory, hematological, or endocrine system, etc.) diseases or medical history.~* Taking any medication, including traditional Chinese medicine;~* Having taken any medication that may affect test results within two weeks before the screening, such as antibiotics, NSAIDs, aluminum- or magnesium-containing antacids, diuretics, anticoagulants, central nervous system depressants, and any drug that may affect the drug absorption;~* Having participated in other investigational drug trial in the preceding three months;~* Blood donation for 360 ml or more within three months before the screening;~* Heart rate\<50 bpm or \>100 bpm;~* Systolic blood pressure \< 90 mmHg or ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg or \< 60 mmHg;~* Women who are pregnant or breastfeeding, or who may be pregnant without adopting acceptable contraception, or who have a positive result in serum pregnancy test;~* Women who are planning to become pregnant within 6 months, or male subjects who are planning to make his spouse pregnant within 6 months;~* HBsAg, HCV antibody, HIV antibody, and Treponema Pallidum antibody positive;~* Urine drug-of-abuse testing positive;~* Any other factor that makes the subject not suitable for the trial as indicated by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Banapenem B1 group (Type: EXPERIMENTAL): Dose in the 1st period 250mg; Dose in the 2nd period 500mg; Dose in the 3rd period 1000mg
- Banapenem B2group (Type: EXPERIMENTAL): Dose in the 1st period 500mg; Dose in the 2nd period 1000mg; Dose in the 3rd period 250mg
- Banapenem B3group (Type: EXPERIMENTAL): Dose in the 1st period 1000mg; Dose in the 2nd period 250mg; Dose in the 3rd period 500mg
- Banapenem C1group (Type: EXPERIMENTAL): 250mg Once daily for 7 consecutive days
- Banapenem C2group (Type: EXPERIMENTAL): 500mg Once daily for 7 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete